Published Date: 13 Mar 2023
Five out of six patients with relapsed or recurrent lymphoma responded to venetoclax alone or in combination with rituximab.
Read Full NewsBrexpiprazole is linked to reduced symptoms, improved functioning, and greater response compared with placebo in patients with early-episode schizophrenia, new research shows.
But the CMS’s cancer-focused alternative payment model’s losses “mask successes” that should serve as lessons, experts say.
1.
Accurately identified high-grade prostate cancer through urine testing.
2.
In cases of metastatic or recurrent head and neck cancer, gene-guided immunotherapy falls short.
3.
Targeted radiation offers promise in patients with metastasized small cell lung cancer to the brain
4.
How a new light-based cancer treatment could destroy tumors without harming healthy cells—using LEDs
5.
FDA Investigating Blood Cancer Risk With Gene Therapy Skysona
1.
Radiation in Oncology: Advances, Applications, and Accessibility
2.
Emerging Dysregulated Signaling Pathways in Early-Onset Colorectal Cancer
3.
Biomimetic Nanovesicles for Breast Cancer: Targeting Senescence to Overcome Chemoresistance
4.
The Statistical Frontier of Hematology Oncology: Diagnostics, Therapies, and Future Horizons in Hematology Oncology 2025
5.
Demystifying Lymphocytes: Everything You Need to Know
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
2.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
3.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
4.
Navigating the Complexities of Ph Negative ALL - Part XII
5.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation